Clinical trial
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
NCT00253318 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00253318 |
|---|---|
| Title | RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer |
| Official title | Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, RAD001, Dexamethasone |
| Enrollment | 15 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 27, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: